 | |
| Company type | Public (Société Anonyme) |
|---|---|
| Euronext Paris: ALMKT | |
| ISIN | FR0010609263 |
| Industry | Medical Technology |
| Founded | 2000 |
| Headquarters | Paris, France |
Key people | Sacha Loiseau, Ph.D Founder, Chairman of the Board and CEO |
| Products | Cellvizio |
Number of employees | 65 |
| Website | www.maunakeatech.com |
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.[citation needed]
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange.